# US 2001/0024659 A1 · Controlled release metformin formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024659 A1
- Document ID: US20010024659A1
- Status: Published application
- Kind: A1
- Application number: 09/726,193
- Filed: 2000-11-29
- Published: 2001-09-27
- Earliest claimed: 1998-03-20
- Assignees: Andrx Corporation
- Inventors: Chih-Ming Chen; Xiu Xiu Cheng; Steve Jan; Joseph Chou
- Web page: https://patentgrep.com/patent/US20010024659A1

## CPC

- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.

## Claims

### Claim 1

A sustained release pharmaceutical formulation comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof, wherein said formulation provides therapeutic plasma levels of said antihyperglycemic drug to a human patient over a 24 hour period after administration to said patient.

### Claim 2 (depends on 1)

The sustained release pharmaceutical formulation of claim 1 wherein said administration is with or shortly after the evening meal.

### Claim 3 (depends on 1)

The sustained release pharmaceutical formulation of claim 1 wherein the bioavailability of the antihyperglycemic drug is increased by the presence of food.

### Claim 4 (depends on 1)

The sustained release pharmaceutical formulation of claim 1 wherein said formulation provides a Tmax of the antihyperglycemic drug which occurs at a time from about 8 hours to about 12 hours after administration to said human patient.

### Claim 5 (depends on 1)

The sustained release pharmaceutical formulation of claim 1 wherein said antihyperglycemic drug is metformin.

### Claim 6

A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation providing a Tmax of the metformin which occurs at a time from about 8 hours to about 12 hours after administration to a human patient.

### Claim 7 (depends on 6)

The sustained release pharmaceutical formulation of claim 6 wherein said administration is with or shortly after the evening meal.

### Claim 8

A sustained release pharmaceutical formulation comprising metformin or a pharmaceutically acceptable salt thereof, said formulation suitable for once daily dosing and providing a peak of a mean plasma concentration/time curve of metformin at a time from about 4 hours to about 10 hours after administration.

### Claim 9

A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation when administered with or after a meal to a human patient, providing a Cmax of metformin from about 52.8% to about 75.1% of the Cmax provided by an equivalent dose of metformin in an immediate release reference formulation.

### Claim 10 (depends on 9)

The sustained release pharmaceutical formulation of claim 9 wherein said formulation provides a Tmax of the metformin which occurs at a time from about 8 hours to about 12 hours after administration to said human patient.

### Claim 11 (depends on 9)

The sustained release pharmaceutical formulation of claim 9 wherein the bioavailability of the drug is increased by the presence of food.

### Claim 12

A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation when administered with or after a meal to a human patient, providing a Tmax of metformin from about 182% to about 200% of the Tmax provided by an equivalent dose of metformin in an immediate release reference formulation.

### Claim 13 (depends on 12)

The sustained release pharmaceutical formulation of claim 12 wherein said formulation provides a Tmax of the metformin which occurs at a time from about 8 hours to about 12 hours after administration to said human patient.

### Claim 14 (depends on 12)

The sustained release pharmaceutical formulation of claim 12 wherein the bioavailability of the metformin is increased by the presence of food.

### Claim 15

A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation when administered in the fasted state to a human patient, providing a Tmax of metformin from about 173% to about 215% of the Tmax provided by an equivalent dose of metformin in an immediate release reference formulation.

### Claim 16 (depends on 15)

The sustained release pharmaceutical formulation of claim 15 wherein said formulation provides a Tmax of the metformin which occurs at a time from about 8 hours to about 12 hours after administration to a human patient.

### Claim 17 (depends on 15)

The sustained release pharmaceutical formulation of claim 15 wherein the bioavailability of the metformin is increased by the presence of food.

### Claim 18

A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation upon administration to a human patient, providing a width at 50% of the height of a mean plasma concentration/time curve from about 6 hours to about 12 hours.

### Claim 19 (depends on 18)

The sustained release pharmaceutical formulation of claim 18 wherein said formulation provides a Tmax of the metformin which occurs at a time from about 8 hours to about 12 hours after administration.

### Claim 20 (depends on 18)

The sustained release pharmaceutical formulation of claim 18 wherein the bioavailability of the metformin is increased by the presence of food.

### Claim 21

A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, wherein a single administration of said formulation provides a lower mean fluctuation index in the plasma than a single administration of a substantially equal dose of an immediate release composition of metformin.

### Claim 22 (depends on 21)

The sustained release pharmaceutical formulation of claim 21 wherein said formulation provides a Tmax of the metformin which occurs at a time from about 8 hours to about 12 hours after administration to a human patient.

### Claim 23 (depends on 21)

The sustained release pharmaceutical formulation of claim 21 wherein the bioavailability of the metformin is increased by the presence of food.

### Claim 24

A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37° C.:
after 2 hours 0-25% of the metformin or salt thereof is released;
after 4 hours 10-45% of the metformin or salt thereof is released;
after 8 hours 30-90% of the metformin or salt thereof is released;
after 12 hours not less than 50% of the metformin or salt thereof is released;
after 16 hours not less than 60% of the metformin or salt thereof is released;
and after 20 hours not less than 70% of the metformin or salt thereof is released.

### Claim 25 (depends on 24)

The sustained release pharmaceutical formulation of claim 24 wherein after administration to a human patient, said formulation provides a bioavailability of metformin which is increased by the presence of food.

### Claim 26 (depends on 24)

The sustained release pharmaceutical formulation of claim 24 wherein after administration to a human patient, said formulation provides a Tmax of metformin which occurs at a time from about 8 hours to about 12 hours after said administration.

### Claim 27

A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37° C.:
after 2 hours 0-15% of the metformin or salt thereof is released;
after 4 hours 20-40% of the metformin or salt thereof is released;
after 8 hours 45-90% of the metformin or salt thereof is released;
after 12 hours not less than 60% of the metformin or salt thereof is released;
after 16 hours not less than 70% of the metformin or salt thereof is released;
and after 20 hours not less than 80% of the metformin or salt thereof is released.

### Claim 28 (depends on 27)

The sustained release pharmaceutical formulation of claim 27 wherein after administration to a human patient, said formulation provides a bioavailability of metformin which is increased by the presence of food.

### Claim 29 (depends on 27)

The sustained release pharmaceutical formulation of claim 27 wherein after administration to a human patient, said formulation provides a Tmax of metformin which occurs at a time from about 8 hours to about 12 hours after said administration.
